Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:00:44.063Z.
Calculation as of: 2026-10-06T18:00:44.063Z.
Quote observation: 2026-10-06T18:00:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9f7ef7d03019e78f4201474ef0c74f9c2a497de6c29d743f28e52983e243880
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2024-04-10.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$3.09B
EV/FCF Ratio
N/A
TTM Avg
15.31x
3Y Avg
19.99x
5Y Avg
19.99x
Market Cap
$3.03B
EV/FCF Ratio
79.49x
TTM Avg
109.02x
3Y Avg
109.02x
5Y Avg
109.02x
Market Cap
$3.19B
EV/FCF Ratio
49.94x
TTM Avg
51.28x
3Y Avg
51.28x
5Y Avg
50.61x
Market Cap
$2.80B
EV/FCF Ratio
40.38x
TTM Avg
54.95x
3Y Avg
90.13x
5Y Avg
90.13x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | $3.08B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.09B | N/A | 15.31x | 19.99x | 19.99x |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.03B | 79.49x | 109.02x | 109.02x | 109.02x |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.99B | N/A | N/A | N/A | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 49.94x | 51.28x | 51.28x | 50.61x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.84B | N/A | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | N/A | N/A | N/A | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.35B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 40.38x | 54.95x | 90.13x | 90.13x |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 52.38x | 69.55x | 89.95x | 89.95x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2024-04-10 | 0.40x |
| 2024-04-09 | 1.76x |
| 2024-04-08 | 1.89x |
| 2024-04-05 | 1.44x |
| 2024-04-04 | 1.37x |
| 2024-04-03 | 1.50x |
| 2024-04-02 | 1.44x |
| 2024-04-01 | 2.02x |
| 2024-03-28 | 2.86x |
| 2024-03-27 | 3.12x |
| 2024-03-26 | 2.21x |
| 2024-03-25 | 2.02x |
| 2024-03-22 | 2.21x |
| 2024-03-21 | 3.06x |
| 2024-03-20 | 3.70x |
| 2024-03-19 | 3.44x |
| 2024-03-18 | 2.99x |
| 2024-03-15 | 5.45x |
| 2024-03-14 | 5.00x |
| 2024-03-13 | 6.75x |
| 2024-03-12 | 6.75x |
| 2024-03-11 | 9.08x |
| 2024-03-08 | 6.23x |
| 2024-03-07 | 107.39x |
| 2024-03-06 | 107.91x |
| 2024-03-05 | 106.61x |
| 2024-03-04 | 108.49x |
| 2024-03-01 | 105.70x |
| 2024-02-29 | 106.61x |
| 2024-02-28 | 111.28x |
| 2024-02-27 | 107.58x |
| 2024-02-26 | 98.25x |
| 2024-02-23 | 98.83x |
